Ocular Therapeutix Inc (OCUL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.99 (-1.48%), Market cap $1.76B, 52-week low–high $6.88 ~ $16.11.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phas
Financial statements, price targets, institutional (13F) holdings and related news for Ocular Therapeutix Inc are updated in real time on BlackAll Trade.
Ocular Therapeutix Inc trades at $9.99 (-1.48%). Real-time quotes and charts are available on BlackAll Trade.
Ocular Therapeutix Inc has a market cap of about $1.76B.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-base